A new era for anticoagulants

European Journal of Internal Medicine

Volumn 20, Issue 6, 2009, Pages 562-568

  Franchini, Massimo ^a   Mannucci, Pier Mannuccio ^b  

^a Department of Pathology   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Anticoagulants; Factor Xa inhibitors; Orthopedic surgery; Thrombin inhibitors; Thromboprophylaxis; Venous thromboembolism

Indexed keywords

ACETYLSALICYLIC ACID; APIXABAN; DABIGATRAN ETEXILATE; DALTEPARIN; ENOXAPARIN; FONDAPARINUX; HEPARIN; IDRAPARINUX; RIVAROXABAN; WARFARIN; XIMELAGATRAN;

ACUTE CORONARY SYNDROME; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; HUMAN; ISCHEMIA; LUNG EMBOLISM; RANDOMIZED CONTROLLED TRIAL; REVIEW; STROKE; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; FACTOR XA; HUMANS; POLYSACCHARIDES; THROMBIN; THROMBOEMBOLISM;

EID: 70349435950     PISSN: 09536205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejim.2009.05.004     Document Type: Review

References (61)

1. Hoppensteadt D.A., Jeske W., Walenga J., and Fareed J. The future of anticoagulation. Semin Respir Crit Care Med 29 (2008) 90-100
2. Bauer K.A. New anticoagulants. Curr Opin Hematol 15 (2008) 509-515
3. Bates S.M., and Weitz J.I. New anticoagulants: beyond heparin, low-molecular-weight heparin and warfarin. Br J Pharmacol 14 (2005) 1017-1028
4. Hart R.G., Benavente O., McBride R., and Pearce L.A. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 131 (1999) 492-501
5. Hirsh J., O'Donnell M., and Eikelboom J.W. Beyond unfractionated heparin and warfarin: current and future advances. Circulation 116 (2007) 552-560
6. Hirsh J., and Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 3 Suppl (2004) 133S-203S
7. Weitz J.L. Low-molecular-weight heparins. N Engl J Med 337 (1997) 688-698
8. Hirsh J., O'Donnell M., and Weitz J.I. New anticoagulants. Blood 105 (2005) 453-463
9. Weitz J.I., and Bates S.M. New anticoagulants. J Thromb Haemost 3 (2005) 1843-1853
10. Fareed J., Hoppensteadt D.A., Fareed D., Demir M., Wahi R., Clarke M., et al. Survival of heparins, oral anticoagulants, and aspirin after the year 2010. Semin Thromb Hemost 34 (2008) 58-73
11. Harenberg J. Development of new anticoagulants: present and future. Semin Thromb Haemost 34 (2008) 779-793
12. Harenberg J., and Wehling M. Current and future prospects for anticoagulant therapy: inhibitors of factor Xa and factor IIa. Semin Thromb Haemost 34 (2008) 39-57
13. Agrawal Y.K., Vaidya H., Bhatt H., Manna K., and Brahmkshatriya P. Recent advances in the treatment of thromboembolic diseases: venous thromboembolism. Med Res Rev 27 (2007) 891-914
14. Bijsterveld N.R., Moons A.H., Boekholdt S.M., van Aken B.E., Fennema H., Peters R.J., et al. Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation 106 (2002) 2550-2554
15. Petitou M., Duchaussoy P., Herbert J.M., Duc G., El Hajji M., Branellec J.F., et al. The synthetic pentasaccharide fondaparinux: first in the class of antithrombotic agents that selectively inhibit coagulation factor Xa. Semin Thromb Haemost 28 (2002) 393-402
16. Eriksson B.I., Bauer K.A., Lassen M.R., and Turpie A.G. Steering Committee of the Pentasaccharide in Hip-Fracture Surgery Study. Fondaparinux compared with enoxaparin for the prevention of VTE after hip-fracture surgery. N Engl J Med 345 (2001) 1298-1304
17. Lassen M.R., Bauer K.A., Eriksson B.I., and Turpie A.G. European Pentasaccharide Elective Surgery Study (EPHESUS) Steering Committee. Postoperative fondaparinux versus preoperative enoxaparin for prevention of VTE in elective hip-replacement surgery: a randomised double-blind comparison. Lancet 359 (2002) 1715-1720
18. Turpie A.G., Bauer K.A., Eriksson B.I., and Lassen M.R. PENTATHLON 2000 Study Steering Committee. Postoperative fondaparinux versus postoperative enoxaparin for prevention of VTE after elective hip replacement surgery: a randomised double-blind trial. Lancet 359 (2002) 1721-1726
19. Bauer K.A., Eriksson B.I., Lassen M.R., and Turpie A.G. Steering Committee of the Pentasaccharide in Major Knee Surgery Study. Fondaparinux compared with enoxaparin for the prevention of VTE after elective major knee surgery. N Engl J Med 345 (2001) 1305-1310
20. Turpie A.G., Bauer K.A., Eriksson B.I., and Lassen M.R. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med 162 (2002) 1833-1840
21. Eriksson B.I., and Lassen M.R. PENTasaccharide in HIp-FRActure Surgery Plus Investigators. Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled, double-blind study. Arch Intern Med 163 (2003) 1733-1742
22. Agnelli G., Bergqvist D., Cohen A.T., Gallus A.S., and Gent M. PEGASUS investigators. Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery. Br J Surg 92 (2005) 1212-1220
23. Cohen A.T., Davidson B.L., Gallus A.S., Lassen M.R., Prins M.H., Tomkowski W., et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ 332 (2006) 325-329
24. Buller H.R., Davidson B.L., Decousus H., Gallus A., Gent M., Piovella F., et al. Matisse Investigators. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med 140 (2004) 867-873
25. Matisse Investigators. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 349 (2003) 1695-1702
26. Yusuf S., Mehta S.R., Chrolavicius S., Afzal R., Pogue J., Granger C.B., et al. Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 354 (2006) 1464-1476
27. Yusuf S., Mehta S.R., Chrolavicius S., Afzal R., Pogue J., Granger C.B., et al. OASIS-6 Trial Group. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA 295 (2006) 1519-1530
28. Mehta S.R., Boden W.E., Eikelboom J.W., Flather M., Steg P.G., Avezum A., et al. OASIS 5 and 6 Investigators. Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST- and non-ST-segment elevation acute coronary syndromes: an individual patient-level combined analysis of the Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) randomized trials. Circulation 118 (2008) 2038-2046
29. Buller H.R., Cohen A.T., Davidson B., Decousus H., Gallus A.S., Gent M., et al. van Gogh Investigators. Idraparinux versus standard therapy for venous thromboembolic disease. N Engl J Med 357 (2007) 1094-1104
30. Buller H.R., Cohen A.T., Davidson B., Decousus H., Gallus A.S., Gent M., et al. van Gogh Investigators. Extended prophylaxis of venous thromboembolism with idraparinux. N Engl J Med 357 (2007) 1105-1112
31. Bousser M.G., Bouthier J., Bousser M.G., Bouthier J., Büller H.R., Cohen A.T., et al. Amadeus Investigators. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, noninferiority trial. Lancet 371 (2008) 315-321
32. Harenberg J., Vukojevic Y., Mikus G., Joerg I., and Weiss C. Long elimination half-life of idraparinux may explain major bleeding and recurrent events of patients from the van Gogh trials. J Thromb Haemost 6 (2008) 890-892
33. Khoo C.W., Tay K.H., Shantsila E., and Lip G.Y. New oral anticoagulants. Int J Clin Pract 63 (2009) 630-641
34. Borris L.C. New compounds in the management of venous thromboembolism after orthopedic surgery: focus on rivaroxaban. Vasc Health Risk Manag 4 (2008) 855-862
35. Eriksson B.I., Borris L.C., Friedman R.J., Haas S., Huisman M.V., Kakkar A.K., et al. RECORD1 Study Group. Rivaroxaban versusenoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 358 (2008) 2765-2775
36. Kakkar A.K., Brenner B., Dahl O.E., Eriksson B.I., Mouret P., Muntz J., et al. RECORD2 Investigators. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 372 (2008) 31-39
37. Lassen M.R., Ageno W., Borris L.C., Lieberman J.R., Rosencher N., Bandel T.J., et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 358 (2008) 2776-2786
38. Turpie A.G., Bauer K.A., and Davidson B. Comparison of rivaroxaban, an oral direct factor Xa inhibitor, and subcutaneous enoxaparin for thromboprophylaxis after total knee replacement (RECORD 4: a phase III study). Proceedings of the 9th EFORT Congress, Nice, May 30, 2008 (2008) Abstract F85
39. Agnelli G., Gallus A., Goldhaber S.Z., Haas S., Huisman M.V., Hull R.D., et al. ODIXa-DVT Study Investigators. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in patients with acute symptomatic Deep-Vein Thrombosis) study. Circulation 116 (2007) 180-187
40. Buller H.R., Agnelli G., Cohen A., Gallus A.S., Misselwitz F., Raskob G., et al. Einstein-DVT Dose-Ranging Study investigators. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study. Blood 112 (2008) 2242-2247
41. Haas S. Rivaroxaban - an oral, direct Factor Xa inhibitor: lessons from a broad clinical study programme. Eur J Haematol 2009;82:339-49.
42. Lassen M.R., Davidson B.L., Gallus A., Pineo G., Ansell J., and Deitchman D. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J Thromb Haemost 5 (Dec 2007) 2368-2375
43. Buller H., Deitchman D., Prins M., and Segers A. Botticelli Investigators, Writing Committee. Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. J Thromb Haemost 6 (2008) 1313-1318
44. Turpie A.G. The top 4 advances in antithrombotic care in the last year. Thromb Res 123 (2008) S2-S6
45. Bauer K.A. New anticoagulants. Hematology Am Soc Hematol Educ Program (2006) 450-456
46. Eriksson B.I., Dahl O.E., Rosencher N., Kurth A.A., van Dijk C.N., Frostick S.P., et al. RE-NOVATE Study Group. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, noninferiority trial. Lancet 370 (2007) 949-956
47. Eriksson B.I., Dahl O.E., Rosencher N., Kurth A.A., van Dijk C.N., Frostick S.P., et al. RE-MODEL Study Group. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the REMODEL randomized trial. J Thromb Haemost 5 (2007) 2178-2185
48. Ginsberg J.S., Davidson B.L., Comp P.C., Francis C.W., Friedman R.J., Huo M.H., et al. RE-MOBILIZE Writing Committee. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 24 (2009) 1-9
49. Ezekowitz M.D., Simmers T.A., Nagarakanti R., Parcham-Azad K., Pedersen K.E., Lionetti D.A., et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol 100 (2007) 1419-1426
50. Colwell C.W., Berkowitz S.D., Davidson B.L., Lotke P.A., Ginsberg J.S., Lieberman J.R., et al. Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, double-blind study. J Thromb Haemost 1 (2003) 2119-2130
51. Francis C.W., Davidson B.L., Berkowitz S.D., Lotke P.A., Ginsberg J.S., Lieberman J.R., et al. Ximelagatran versus warfarin for the prevention of VTE after total knee arthroplasty. Ann Intern Med 137 (2002) 648-655
52. Francis C.W., Berkowitz S.D., Comp P.C., Lieberman J.R., Ginsberg J.S., Paiement G., et al. EXULT A Study Group. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. N Engl J Med 349 (2003) 1703-1712
53. Colwell Jr. C.W., Berkowitz S.D., Lieberman J.R., Comp P.C., Ginsberg J.S., Paiement G., et al. EXULT B Study Group. Oral direct thrombin inhibitor ximelagatran compared with warfarin for the prevention of venous thromboembolism after total knee arthroplasty. J Bone Joint Surg Am 87 (2005) 2169-2177
54. Eriksson B.I., Agnelli G., Cohen A.T., Dahl O.E., Mouret P., Rosencher N., et al. METHRO III Study Group. Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of VTE after total hip or knee joint replacement. Thromb Haemost 89 (2003) 288-296
55. Eriksson B.I., Agnelli G., Cohen A.T., Dahl O.E., Lassen M.R., Mouret P., et al. EXPRESS Study Group. The oral direct thrombin inhibitor ximelagatran, and its subcutaneous form melagatran, compared with enoxaparin for prophylaxis of VTE in total hip or total knee replacement: the EXPRESS study. J Thromb Haemost 1 (2003) 2490-2496
56. Schulman S., Wahlander K., Lundstrom T., Clason S.B., and Eriksson H. THRIVE III Investigators. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med 349 (2003) 1713-1721
57. Fiessinger J.N., Huisman M.V., Davidson B.L., Bounameaux H., Francis C.W., Eriksson H., et al. THRIVE Treatment Study Investigators. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. JAMA 293 (2005) 681-689
58. Olsson S.B. Executive Steering Committee of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 362 (2003) 1691-1698
59. Albers G.W., Diener H.C., Frison L., Grind M., Nevinson M., Partridge S., et al. SPORTIF Executive Steering Committee for the SPORTIF V Investigators. JAMA 293 (2005) 690-698
60. Albers G.W. SPORTIF Investigators. Stroke prevention in atrial fibrillation: pooled analysis of SPORTIF III and V trials. Am J Manag Care 10 14 Suppl (2004) S462-S469
61. Wallentin L., Wilcox R.G., Weaver W.D., Emanuelsson H., Goodvin A., Nyström P., et al. ESTEEM Investigators. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. Lancet 362 (2003) 789-797